Job opening in Novartis India, Hyderabad

Position: Senior Scientist

Job Description
Plan and perform scientific experiments (or pilot plant processes) for the preparation and timely delivery of drug substances (DS), drug products (DP), processes and procedures in collaboration within a multifunctional project team coordinated by a Project leader. Contribute to maintenance of lab instruments/infrastructure.

Your responsibilities include, but are not limited to:
1. Meet quality, quantity and timelines in all assigned projects; Perform and document scientific experiments; Plan & organize scientific experiments under minimal guidance from more experienced team members. Seeks proactively for support and coaching from Project Leader, Scientific Expert or other team members during the whole process if necessary.
2. Provide documentation of raw data; Evaluate and Contribute to interpretation and report results under minimal guidance from more experienced team members. ; Propose and provide input for the design of next experiments. ; Optimize existing methods (lab or plant) or contribute to new method development and reproduce published methods and develop more efficient ones.
3. Generate lab procedures, reports and/or instructions and/or SOP’s. (I, N) ; Actively transfer procedures/instructions to pilot plant or production, including troubleshooting, process steering controls etc.

  • Communicate and address problems, perform safety and literature searches under moderate guidance from more experienced team member.

4. Keep record of and manage chemicals, intermediates, excipients and solvents within own area of responsibility.
5. Collaborate with other team members to facilitate deliveries of DS and/or DP. ; Act as mentors for new joinees.
6. Utilize special tools/equipments and/or specialized facilities e.g., containment/ sterile labs. ; Evaluate new lab equipment. ; Schedule and perform routine maintenance and calibration of lab instruments/equipment & contribute to maintenance of infrastructure/equipment.
7. Actively participate in project teams/meetings/networks. ; Actively contributes to team goals.
8. Ensure all own activities are aligned with overall drug development process. (B) ; Work according to appropriate SOPs, GMP, GLP, QM, HSE, ISEC & Novartis Guidelines ;Strategic and scientific contribution to Networks, target achievements according to net-work charter and annual objectives.

Minimum Requirements

1. PhD on technical subject with 4 years of industrial or relevant experience. or Master of Science with 8 years of relevant experience Fluency in English language.
2. Awareness for safe handling of chemicals, potentially dangerous materials and equipment. Broad theoretical and scientific knowledge in the relevant area (e.g. manufacturing, analytical, pharmaceutical).
3. Skilled scientist with expertise on LCMS and MS/MS analysis including structural elucidation and characterization of impurities, trace level quantification as well as data interpretation.
4. Experience on dealing OOS/OOE and deviations involving above mentioned analytical techniques.
5. Proficient with laboratory and/or technical tools. Good knowledge of software and computer tools.
6. Good documentation skills.
7. Good knowledge of current Good Manufacturing Practices (cGMP) ;Advanced scientific/technical writing skills Wide experience on de-formulation studies of the drug products , especially in the microscopic evaluation of drug component.

Apply here: https://www.linkedin.com/jobs/view/2356049717/

Job opening in Beckman Coulter

Position: Development Scientist (Assay Development – Flow Cytometry)

Summary of responsibilities:

Assists in the evaluation and implementation of new technologies. The incumbent performs experiments, analyzes data and plans next series of experiments, takes ownership for the assigned work participates in planning studies for the development, evolution and optimization of assay(s);

Prepares study plans and reports, maintains well organized laboratory notebooks in compliance with relevant procedures; and supports post-launch to resolve performance and/or quality issues.

Boundary Conditions/Authority Levels:

Normally receives no instruction on routine work; general instructions on new assignments. Adheres to policies and procedures.

Essential Duties and Responsibilities: include the following. Other duties may be assigned.

  • Participates in the analysis, design and development of system applications.
  • Follows standard practices and procedures in analyzing situations or data from which answers can be readily obtained.
  • Reports status of experiments to supervisor/Technical lead.
  • Applies analytical skills to interpret data and uses independent judgment and discretion in developing solutions to a variety of work problems of moderate scope and complexity
  • Able to troubleshoot issues, identify root cause and strive towards solutions for identified problems
  • Responsible for creating technical presentations and updating relevant functions on the same
  • Responsible for generating high quality technical documents and reports
  • Responsible for strict adherence to quality standards and regulatory guidelines
  • Responsible for communicating business related issues or opportunities to next management level.
  • Responsible for ensuring personal and company compliance with all Federal, State, local and company regulations, policies and procedures for Health, Safety and Environmental compliance.
  • Performs other related duties as required.

Education and/or Experience:

PhD in Life Sciences/Microbiology/ Biochemistry/Biotechnology or relevant fields with 2+ years of experience ; Master’s degree in Microbiology/ Biochemistry/Biotechnology or relevant fields with 5+ years of relevant experience in industry.

Industrial experience in the field of assay development of Flow cytometry reagents, ELISAs or other Immunological techniques is desirable but not mandatory.

Apply here: https://www.linkedin.com/jobs/view/2413491499/

Time-restricted feeding prevents breast cancer

Dr. Manasi Das did her Master in Life Sciences from Sambalpur University, Odisha, India. After that, she did her Ph.D. from the Institute of Life Sciences, Bhubaneswar, Odisha, India, under the supervision of Dr. Sanjeeb Kumar Sahoo, where she studied on Nanodrug delivery for breast cancer therapy. Presently, she is Postdoctoral Fellow in the Department of Medicine, University of California, San Diego, USA. Her research focuses on understanding the role of time-restricted feeding/eating intervention in breast cancer.
Dr. Deepak Kumar did his Master in Biotechnology from PG Dept. of Biotechnology (Supported by Dept. of Biotechnology, Govt. of India) Utkal University, Odisha, India. After that, he did his Ph.D. from the Institute of Life Sciences, Bhubaneswar, Odisha, India, under the supervision of Dr. Nrisingha Dey, where he studied on Development of promoters with enhanced transgene expression. Presently, he is a Project Scientist in the Department of Medicine, University of California, San Diego, USA. His research focuses on (1) understanding the mechanism of RNA splicing factor involved in obesity, liver metabolism and liver cancer initiation, and progression, (2) investigating the therapeutic potential of time-restricted feeding for obesity induced metabolic disease. Here, Manasi and Deepak talks about their work titled “Time-restricted feeding normalizes hyperinsulinemia to inhibit breast cancer in obese postmenopausal mouse models” published in Nature communications.

How would you explain your papers key results to the non-scientific community?

Dr. Manasi Das
Dr. Deepak Kumar

We found that restricting access to food to an eight-hour window when physical activity is highest delayed breast cancer formation, inhibited growth of existing tumors, and reduced cancer metastases to the lung. We observed this inhibition in multiple models of postmenopausal breast cancer in obese mice with both hormone-dependent tumors and triple-negative, hormone-independent tumors.

Figure 1. Time-restricted feeding during active phase improves metabolism and inhibits obesity driven postmenopausal breast cancer.

What are the possible consequences of these findings for your research area?

We had previously published that when mice overeat a highly caloric diet and become obese, breast cancer is greatly accelerated. We had also found that feeding the mice a similar diet but supplementing with omega-3 fatty acids would reduce insulin resistance and tumor growth. Our group, and others, had published that using time-restricted access to food (TRF) could similarly reduce insulin resistance, and we now report in our recent publication that TRF inhibits breast cancer. Is this mouse study relevant to human health? Although large scale studies have not been performed, a number of small studies have shown that increasing the length of time between the last meal of the day and breakfast the next morning (i.e. increasing the length of the overnight fast), which is analogous to TRF in mice, has beneficial effects in humans by improving metabolism and reducing insulin resistance. One of our colleagues Dr. Sears has published pidemiological evidence that a longer overnight fast is associated with reduced risk of breast cancer, and similar associations have been seen in prostate and pancreatic cancer. We believe our findings in the mouse study provide strong, mechanism-based evidence for adopting time-restricted eating to reduce insulin resistance and protect against obesity-driven breast cancer in humans. Our findings support the possibility that a simple dietary manipulation through time restricted eating might be a potential non-pharmacological and practical way to achieve beneficial effect in breast cancer therapy.

“Our findings support the possibility that a simple dietary manipulation through time restricted eating might be a potential non-pharmacological and practical way to achieve beneficial effect in breast cancer therapy.”

What was the exciting moment (eureka moment) during your research?

The most exciting moment was during the first TRF experiments with hormone-dependent breast cancer. This model involved introducing breast cancer tumor cells into the mammary glands in mice. The cells were already cancerous and we were just measuring how quickly the tumor grew. We were delighted to see that the tumors in the obese mice on TRF grew much slower, at a rate no different from that in lean, healthy mice. So the TRF had completely eliminated the effect of obesity to accelerate tumor growth.

What do you hope to do next?

The beauty of prolonged overnight fasting is that people are asleep during most of the fasting period, so they are not bothered by hunger. This is very different from other forms of intermittent fasting that involve reducing caloric intake during the day. If prolonged nightly fasting is proven to be effective at preventing cancer incidence or reoccurrence, it would be relatively easy to draft nutritional recommendations for cancer patients. We are currently pursuing a randomized control clinical trial in cancer survivors to see if prolonged nightly fasting will prevent a recurrence.

Where do you seek scientific inspiration?

Obesity is a worldwide health problem. Obese populations have a higher incidence of endometrial, colorectal, prostate, pancreatic and postmenopausal breast cancer. One in eight women will be diagnosed with breast cancer during their lifetime. Breast cancer is strongly associated with age as the incidence is 42/100,000 for women <50 years of age, but 327/100,000 for age >50 and 398/100,000 for age >60. The epidemiologic evidence for obesity – breast cancer connection is particularly strong: several studies across diverse populations show that breast cancer risk increases by 40% in obese post-menopausal women. Obesity is associated with a greater than 2-fold increase in breast cancer risk in post-menopausal women. Furthermore, obesity is associated with a higher incidence of aggressive triple-negative tumors and reduced survival, regardless of menopausal status.

How do you intend to help Indian science improve?

Considering the increased risk obesity poses for several cancer types, practical strategies to reduce obesity’s harmful sequelae could have a far-reaching impact. Dietary intervention is a potential means to mitigate this risk. Dieting (caloric restriction) and intermittent fasting are beneficial to metabolic health and reverse many of the detrimental effects of obesity. These beneficial effects also extend to cancer. For many years, it has been known that caloric restriction inhibits tumor growth in animals and sensitizes cancer cells to chemo- and radiation therapy. Despite promising animal data and considerable evidence for human health benefits, clinics have not adopted these dietary interventions as most of these fasting regimes require active intervention by nutritionists or clinical researchers to ensure compliance. While these interventions may work in the short-term to correct metabolic dysfunction, they are not suitable for long-term use at home due to low compliance in the obese population, particularly as daytime fasting is associated with hunger and irritability. A prolonged nightly fasting nutritional intervention, which has the same health benefits as a caloric restriction but is easier to maintain, would greatly increase long-term compliance and have a major impact on Indian health.

Reference

Das, M., Ellies, L.G., Kumar, D. et al. Time-restricted feeding normalizes hyperinsulinemia to inhibit breast cancer in obese postmenopausal mouse models. Nat Commun 12, 565 (2021). https://doi.org/10.1038/s41467-020-20743-7

Email: dpkbiotech@gmail.com

Press release: https://health.ucsd.edu/news/releases/Pages/2021-when-not-what-obese-mice-ate-reduced-breast-cancer-risk.aspx and https://www.nutritioninsight.com/news/time-restricted-feeding-may-inhibit-breast-cancer-shows-study-of-obese-postmenopausal-mice.html

Job opening in Clonz Biotech

Clonz biotech is hiring for managers for their Biosimilars GMP manufacturing facility in Hyderabad.

Position 1: Manager Quality Control

Preferentially the candidate should have a sound knowledge of Biosimilars QC testing and release under GMP environment with about 6-10years experience in biologics.

Position 2: Manager Downstream

Preferentially the candidate should have a sound knowledge of Biosimilars purification systems under GMP environment with about 6-10years experience in biologics.

If you feel the above criteria matches your profile, please send your resume to satyanarayana.rajulapati@clonzbio.com

Bio Patrika interviews Dr. Kasoju on his thoughts about “Tissue engineering using novel cell culture inserts”

Dr. Naresh Kasoju’s interview with Bio Patrika hosting “Vigyan Patrika”, a series of author interviews. Dr. Kasoju is a Scientist in Applied Biology from Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology (An Institute of National Importance, Dept. of Science and Technology, Govt. of India), Thiruvananthapuram, India. Earlier, he obtained Ph.D. from the Department of Biotechnology, Indian Institute of Technology, Guwahati, India in 2012, followed by post-doctoral training from the Institute of Macromolecular Chemistry, Prague, Czech Republic, Department of Zoology and Institute of Biomedical Engineering, University of Oxford, Oxford, UK. His research interests include fabrication of novel biomaterial structures, understanding cell-material interactions and development of tissue-engineered constructs.

How would you explain your paper’s key results to the non-scientific community?

Tissue engineering is a multidisciplinary field aiming to fabricate human tissue constructs in the laboratory. The process typically involves (a) development of a template material, referred as a scaffold, (b) isolation and culture of human cells on this scaffold and (c) in vitro maturation of cell-laden scaffold into a 3D tissue, which looks and acts like a true human tissue in the body. Here, the template material i.e. the scaffold is the key player. Typically, these scaffolds are made of materials that are compatible with human cells, termed as biomaterials. Even though tissue engineering started from the 1990s, and it made significant progress. However, fabricating a tissue that mimics native architecture remains one of the major challenges in the field.

Figure 1. Schematic representation of tissue engineering skin using novel inserts, including storage and shipping.

In this project, we successfully fabricated spatially organized skin tissue constructs having epidermal and dermal equivalent histology. The core of the study was a novel dual cell seeding compatible insert clipped with electrospun nanofibrous silk fibroin scaffold (Figure 1). These inserts were designed to be versatile in terms of dimensions and functions. They can be flipped upside down and can be seeded with cells on either side to develop a co-cultured tissue. Adding to this, the inserts were designed so that the cell-laden scaffolds can be stacked in multiple numbers and conveniently packed in a container for storage as well as shipping purpose. Therefore, these inserts allow a continuous workflow to translate bioengineered co-cultured tissues from bench-to-bedside. The resultant tissue constructs can be explored as tissue substitutes or as models for drug and chemical screening applications.

What are the possible consequences of these findings for your research area?

There are commercial cell culture inserts available in the market which often used in cell culture. However, these inserts come with a pre-fixed membrane and used for single-cell culture but, the tissue engineers require an insert that allows the user to clip a customized scaffold and culture more than one type of cell. Our product stands out from the commercial items in many ways, and it can provide a continuous workflow from cell culture in the lab to its application on the wound site of the patient in the clinic. We believe this technology would expedite the co-cultured tissue engineering from bench-to-bedside.

“We believe this technology would expedite the co-cultured tissue engineering from bench-to-bedside.”

What was the exciting moment (eureka moment) during your research?

As far as this particular project is concerned, the moment we found a problem with the regular inserts, we immediately started drawing various designs, and we made few prototypes. Though the design published in the paper was our favourite, we were sceptical since we can’t predict how cells would respond. We started wet lab work and we cultured human skin cells on it. Subsequently, the moment we saw the microscope images with well-organized skin-like tissue, we felt that eureka moment.

What do you hope to do next?

The published work is a mere proof of concept study showing the design of a dual cell seeding compatible insert and a method of fabricating co-cultured tissue constructs with it. We are working on this concept in multiple dimensions to explore the applications of the tissue-engineered constructs in transplantation, toxicological or drug screening applications. We are actively looking for academic partners to develop this technology further. We have filed an Indian patent application (number 201941053786) and an Indian design registration (number 324417-001) based on this study, and we are actively looking for industrial partners to make this technology a reality.

Where do you seek scientific inspiration?

Nature! – the most apparent answer from any biologist. Be it a flying butterfly or a stationary rock, everything has a story to tell. If we look at any living system in general or the human body in particular, it is such a gigantic system with an enormous number of biomolecules and networks of interaction amongst them, yet it does everything to perfection; It has an answer for any challenge* that you throw to it (*terms and conditions apply). I am fascinated by such an extraordinary creation of nature, and I always wonder can we ever truly mimic it, at least in part if not full!

How do you intend to help Indian science improve?

In the current education system, we are being encouraged to question nature and the natural phenomenon. But I feel, we must first appreciate nature and the natural phenomenon before questioning it. I mean to say that before asking why the sky is blue, we should, hey, look how beautiful the sky is! This could be possible by effective communication of nature and the natural phenomenon to the masses. There are a few platforms for such science communication in India, however, it is way too less for 135+ crores of the population in the country. Biopatrika is a great initiative, and I wish that it would achieve its aim of reaching the masses effectively. I am thankful to Biopatrika for this opportunity to share my piece of work with you all.

Reference

Jimna M Ameer, Ramesh Babu V, Vinod D, Nishad KV, Sabareeswaran A, Anil Kumar PR, Naresh Kasoju*. Fabrication of co-cultured tissue constructs using a dual cell seeding compatible cell culture insert with a clip-on scaffold for potential regenerative medicine and toxicological screening applications. Journal of Science: Advanced Materials and Devices 2020; 5(2): 207-217. http://doi.org/10.1016/j.jsamd.2020.04.004

Email: naresh.kasoju@sctimst.ac.in

Website: www.sctimst.ac.in/people/naresh.kasoju

Edited by: Govinda Raju Yedida (Volunteer, Bio Patrika)

Job opening in Lilac Insights

Vacancy: Scientific Officer in Onco Cytogenetics at Lilac Insights Pvt Ltd, Mumbai.

(In the Leadership of Dr. Pratibha Kadam Amare).

Educational Qualification: MSc

Experience: Preferably 3+ Years in Cytogenetics (Cancer genetics would be additional advantage)

Those interested can share email to srinivas@lilacinsights.com

M: +917045695164.

Biosimilar Workshop: Mass Spectrometry for Analysis of Critical Quality Attributes of Biologics/Biosimilars

Biosimilar workshop Digital edition presents Mass Spectrometry Training Program under Accelerate Vigyan Scheme.
Date: 1st – 7th March 2021.
Time: 02:00 PM- 05:00 PM IST
Virtual Workshop (Zoom platform)
Certification course with No registration fees.

If you haven’t register yourself, do it now!!

🔴#Registration link
https://lnkd.in/g8CrP-E

🔴#Live lectures and #demonstration by leading experts.

🔴Note- Only for postgraduate students with #lifescience background and #phd research scholar with biopharma background.

Last date of registration: 22nd February, 2021.

#dontmissout
#massspectrometry #cqa #biologics #biosimilars #biosimilarworkshop #digitaledition #elearning #trainingprogram # #healthcare #research #biopharmaceutical #registrationopen

Ratnesh Jain Utpal Tatu Rainer Bischoff Sanjeeva Srivastava Babu Ponnusamy Mahesh J Kulkarni Dan Bracewell Agilent Technologies